Description:
Technology Summary
The use of EGFR inhibitors in the treatment of NSCLC is well established, even being used as a first-line treatment for certain drugs like Gefitinib and Osimertinib. However, eventual drug-resistance by the tumor to these treatments remains a problem. This technology showcases how CRM1 inhibitor Leptomycin B can potentiate the EGFR inhibitor Gefitinib, diminish resistance, and even resensitize tumor cells to Gefitinib. The technology is a method for using CRM1 inhibitors alongside EGFR inhibitors in lung-cancer treatment to mitigate acquired drug resistance, resensitize resistant tumors, and enhance the potency of the EGFR inhibitor.
Reference Number
D-1448
Market Applications
• Therapeutics
• Oncology
Features, Benefits & Advantages
• The toxic effects of leptomycin B are less severe in a combinational therapy
• Reversal of Gefitinib resistance in NSCLC
• Prevents Gefitinib resistance in NSCLC
Intellectual Property
A provisional patent with a claim set has been filed recently, 4/3/18.
Development Stage
The disclosed technology has been tested in-vitro in cancer cell lines.
Researchers
Dr. Weimin Gao, Associate Professor, Department of Environmental Toxicology and the Institute of Environmental and Human Health, Texas Tech University System.
Keywords
Gefitinib, leptomycin B, cancer, NSCLC, treatment, combinational